7Baggers

We provide you with 20 years of free, institutional-grade data for HRMY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HRMY. Explore the full financial landscape of HRMY stock.

Reported DateCIKTickerType
2025-08-051802665HRMY10-QUrl
2025-05-061802665HRMY10-QUrl
2025-02-251802665HRMY10-KUrl
2024-10-291802665HRMY10-QUrl
2024-08-061802665HRMY10-QUrl
2024-04-301802665HRMY10-QUrl
2024-02-221802665HRMY10-KUrl
2023-10-311802665HRMY10-QUrl
2023-08-011802665HRMY10-QUrl
2023-05-021802665HRMY10-QUrl
2023-02-211802665HRMY10-KUrl
2022-11-011802665HRMY10-QUrl
2022-08-021802665HRMY10-QUrl
2022-05-031802665HRMY10-QUrl
2022-02-281802665HRMY10-KUrl
2021-11-091802665HRMY10-QUrl
2021-08-101802665HRMY10-QUrl
2021-05-111802665HRMY10-QUrl
2021-03-251802665HRMY10-KUrl
2020-11-121802665HRMY10-QUrl
2020-07-271802665HRMYS-1Url

Harmony Biosciences Holdings, Inc
(NASDAQ:HRMY) 

HRMY stock logo

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United Sta...

Founded: 2017
Full Time Employees: 150
CEO: John C.s Jacobs  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about HRMY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.